{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T03:28:34Z","timestamp":1786418914192,"version":"build-2736575974"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T00:00:00Z","timestamp":1780099200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:00:00Z","timestamp":1786406400000},"content-version":"vor","delay-in-days":73,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Ratchadapiseksompotch Fund, Faculty of Medicine, Chulalongkorn University","award":["MDCU RA67\/008."],"award-info":[{"award-number":["MDCU RA67\/008."]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Clin Microbiol Antimicrob"],"DOI":"10.1186\/s12941-026-00864-5","type":"journal-article","created":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T10:15:57Z","timestamp":1780136157000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A cross-sectional study on discordances between Anyplex\u2122 II MTB\/MDR and BACTEC MGIT 960 system for assessing susceptibility for Mycobacterium tuberculosis: analysis of clinical specimens from patients with isoniazid-monoresistant, rifampicin-monoresistant, and multidrug-resistant tuberculosis"],"prefix":"10.1186","volume":"25","author":[{"given":"Kanphai","family":"Wongjarit","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pattama","family":"Torvorapanit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suthidee","family":"Petsong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajcharaporn","family":"Sawatpanich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waritta","family":"Sawaengdee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panadda","family":"Dhepakson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suwatchareeporn","family":"Rotcheewaphan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gompol","family":"Suwanpimolkul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,30]]},"reference":[{"issue":"1","key":"864_CR1","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1111\/tmi.13502","volume":"26","author":"P Kamolwat","year":"2021","unstructured":"Kamolwat P, Nateniyom S, Chaiprasert A, Disratthakit A, Mahasirimongkol S, Yamada N, Smithtikarn S. Prevalence and associated risk factors of drug-resistant tuberculosis in Thailand: results from the fifth national anti-tuberculosis drug resistance survey. Trop Med Int Health. 2021;26(1):45\u201353.","journal-title":"Trop Med Int Health"},{"issue":"10","key":"864_CR2","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1038\/s41579-024-01025-1","volume":"22","author":"M Farhat","year":"2024","unstructured":"Farhat M, Cox H, Ghanem M, Denkinger CM, Rodrigues C, Abd El Aziz MS, Enkh-Amgalan H, Vambe D, Ugarte-Gil C, Furin J, et al. Drug-resistant tuberculosis: a persistent global health concern. Nat Rev Microbiol. 2024;22(10):617\u201335.","journal-title":"Nat Rev Microbiol"},{"issue":"4","key":"864_CR3","doi-asserted-by":"publisher","first-page":"e0006425","DOI":"10.1128\/cmr.00064-25","volume":"38","author":"HM Yapa","year":"2025","unstructured":"Yapa HM, MacLean E-H, Menzies NA, Dodd PJ, Dean A, Mirzayev F, Schumacher SG, Nguyen LN, Zignol M, Fox GJ. Drug-resistant tuberculosis: a priority pathogen for enhanced public health research and practice. Clin Microbiol Rev. 2025;38(4):e0006425.","journal-title":"Clin Microbiol Rev"},{"key":"864_CR4","unstructured":"WHO consolidated guidelines on tuberculosis. Module 3: diagnosis - rapid diagnostics for tuberculosis detection. WHO Guidelines Approved by the Guidelines Review Committee. Geneva 2021."},{"key":"864_CR5","doi-asserted-by":"publisher","first-page":"794","DOI":"10.3389\/fmicb.2019.00794","volume":"10","author":"TNA Nguyen","year":"2019","unstructured":"Nguyen TNA, Anton-Le Berre V, Banuls AL, Nguyen TVA. Molecular diagnosis of drug-resistant tuberculosis; a literature review. Front Microbiol. 2019;10:794.","journal-title":"Front Microbiol"},{"issue":"4","key":"864_CR6","doi-asserted-by":"publisher","first-page":"e122","DOI":"10.1016\/S1473-3099(22)00875-1","volume":"23","author":"J Dominguez","year":"2023","unstructured":"Dominguez J, Boeree MJ, Cambau E, Chesov D, Conradie F, Cox V, Dheda K, Dudnyk A, Farhat MR, Gagneux S, et al. Clinical implications of molecular drug resistance testing for Mycobacterium tuberculosis: a 2023 TBnet\/RESIST-TB consensus statement. Lancet Infect Dis. 2023;23(4):e122\u201337.","journal-title":"Lancet Infect Dis"},{"key":"864_CR7","unstructured":"Anyplex\u2122 II MTB\/MDR Detection. Seegene Inc. https:\/\/www.seegene.com\/assays\/anyplex2_mtb_mdr_detection Accessed 11 May 2025."},{"issue":"3","key":"864_CR8","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/S1473-3099(18)30673-X","volume":"19","author":"K Zurcher","year":"2019","unstructured":"Zurcher K, Ballif M, Fenner L, Borrell S, Keller PM, Gnokoro J, Marcy O, Yotebieng M, Diero L, Carter EJ, et al. Drug susceptibility testing and mortality in patients treated for tuberculosis in high-burden countries: a multicentre cohort study. Lancet Infect Dis. 2019;19(3):298\u2013307.","journal-title":"Lancet Infect Dis"},{"key":"864_CR9","doi-asserted-by":"publisher","first-page":"870768","DOI":"10.3389\/fimmu.2022.870768","volume":"13","author":"KA Yusoof","year":"2022","unstructured":"Yusoof KA, Garcia JI, Schami A, Garcia-Vilanova A, Kelley HV, Wang SH, Rendon A, Restrepo BI, Yotebieng M, Torrelles JB. Tuberculosis phenotypic and genotypic drug susceptibility testing and immunodiagnostics: a review. Front Immunol. 2022;13:870768.","journal-title":"Front Immunol"},{"issue":"1","key":"864_CR10","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1128\/JCM.02378-13","volume":"52","author":"S Banu","year":"2014","unstructured":"Banu S, Rahman SM, Khan MS, Ferdous SS, Ahmed S, Gratz J, Stroup S, Pholwat S, Heysell SK, Houpt ER. Discordance across several methods for drug susceptibility testing of drug-resistant Mycobacterium tuberculosis isolates in a single laboratory. J Clin Microbiol. 2014;52(1):156\u201363.","journal-title":"J Clin Microbiol"},{"issue":"5","key":"864_CR11","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1093\/jac\/dkz564","volume":"75","author":"A Van Rie","year":"2020","unstructured":"Van Rie A, Whitfield MG, De Vos E, Scott L, Da Silva P, Hayes C, Heupink TH, Sirgel FA, Stevens W, Warren RM. Discordances between molecular assays for rifampicin resistance in Mycobacterium tuberculosis: frequency, mechanisms and clinical impact. J Antimicrob Chemother. 2020;75(5):1123\u20139.","journal-title":"J Antimicrob Chemother"},{"key":"864_CR12","unstructured":"Technical Report on critical concentrations for drug susceptibility testing. of isoniazid and the rifamycins (rifampicin, rifabutin and rifapentine). Global Programme on Tuberculosis and Lung Health (GTB). Geneva 2023."},{"key":"864_CR13","doi-asserted-by":"crossref","unstructured":"CRyPTIC Consortium. Epidemiological cut-off values for a 96-well broth microdilution plate for high-throughput research antibiotic susceptibility testing of M. tuberculosis. Eur Respir J 2022, 60(4).","DOI":"10.1183\/13993003.00239-2022"},{"key":"864_CR14","unstructured":"Clinical and laboratory Standards Institute. Performance standards for susceptibility testing of Mycobacteria, Nocardia spp., and other aerobic Actinomycetes. https:\/\/clsi.org\/shop\/standards\/m24s\/ [Accessed 11 May 2025]."},{"key":"864_CR15","unstructured":"Brabaham Bioinformatics. FastQC: A quality control tool for high throughput sequence data. https:\/\/www.bioinformatics.babraham.ac.uk\/projects\/fastqc\/ [Accessed 11 May 2025]."},{"issue":"15","key":"864_CR16","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1093\/bioinformatics\/btu170","volume":"30","author":"AM Bolger","year":"2014","unstructured":"Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics. 2014;30(15):2114\u201320.","journal-title":"Bioinformatics"},{"issue":"6","key":"864_CR17","doi-asserted-by":"publisher","first-page":"e1005595","DOI":"10.1371\/journal.pcbi.1005595","volume":"13","author":"RR Wick","year":"2017","unstructured":"Wick RR, Judd LM, Gorrie CL, Holt KE, Unicycler. Resolving bacterial genome assemblies from short and long sequencing reads. PLoS Comput Biol. 2017;13(6):e1005595.","journal-title":"PLoS Comput Biol"},{"issue":"8","key":"864_CR18","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1093\/bioinformatics\/btt086","volume":"29","author":"A Gurevich","year":"2013","unstructured":"Gurevich A, Saveliev V, Vyahhi N, Tesler G. QUAST: quality assessment tool for genome assemblies. Bioinformatics. 2013;29(8):1072\u20135.","journal-title":"Bioinformatics"},{"issue":"7","key":"864_CR19","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1101\/gr.186072.114","volume":"25","author":"DH Parks","year":"2015","unstructured":"Parks DH, Imelfort M, Skennerton CT, Hugenholtz P, Tyson GW. CheckM: assessing the quality of microbial genomes recovered from isolates, single cells, and metagenomes. Genome Res. 2015;25(7):1043\u201355.","journal-title":"Genome Res"},{"issue":"1","key":"864_CR20","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s13073-019-0650-x","volume":"11","author":"JE Phelan","year":"2019","unstructured":"Phelan JE, O\u2019Sullivan DM, Machado D, Ramos J, Oppong YEA, Campino S, O\u2019Grady J, McNerney R, Hibberd ML, Viveiros M, et al. Integrating informatics tools and portable sequencing technology for rapid detection of resistance to anti-tuberculous drugs. Genome Med. 2019;11(1):41.","journal-title":"Genome Med"},{"issue":"3","key":"864_CR21","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.cmi.2016.09.006","volume":"23","author":"E Andre","year":"2017","unstructured":"Andre E, Goeminne L, Cabibbe A, Beckert P, Kabamba Mukadi B, Mathys V, Gagneux S, Niemann S, Van Ingen J, Cambau E. Consensus numbering system for the rifampicin resistance-associated rpoB gene mutations in pathogenic mycobacteria. Clin Microbiol Infect. 2017;23(3):167\u201372.","journal-title":"Clin Microbiol Infect"},{"key":"864_CR22","unstructured":"Catalogue of mutations in. Mycobacterium tuberculosis complex and their association with drug resistance, 2nd edition. Global Programme on Tuberculosis and Lung Health (GTB). Geneva 2023."},{"issue":"4","key":"864_CR23","doi-asserted-by":"publisher","first-page":"2501","DOI":"10.1007\/s11033-020-05331-8","volume":"47","author":"N Chumpa","year":"2020","unstructured":"Chumpa N, Kawkitinarong K, Rotcheewaphan S, Sawatpanich A, Petsong S, Tumwasorn S, Suwanpimolkul G. Evaluation of Anyplex II MTB\/MDR kit\u2019s performance to rapidly detect isoniazid and rifampicin resistant Mycobacterium tuberculosis from various clinical specimens. Mol Biol Rep. 2020;47(4):2501\u20138.","journal-title":"Mol Biol Rep"},{"issue":"4","key":"864_CR24","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.diagmicrobio.2017.08.016","volume":"89","author":"Y Igarashi","year":"2017","unstructured":"Igarashi Y, Chikamatsu K, Aono A, Yi L, Yamada H, Takaki A, Mitarai S. Laboratory evaluation of the Anyplex II MTB\/MDR and MTB\/XDR tests based on multiplex real-time PCR and melting-temperature analysis to identify Mycobacterium tuberculosis and drug resistance. Diagn Microbiol Infect Dis. 2017;89(4):276\u201381.","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"1","key":"864_CR25","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1128\/JCM.01904-15","volume":"54","author":"M Sali","year":"2016","unstructured":"Sali M, De Maio F, Caccuri F, Campilongo F, Sanguinetti M, Fiorentini S, Delogu G, Giagulli C. Multicenter evaluation of Anyplex plus MTB\/NTM MDR-TB assay for rapid detection of Mycobacterium tuberculosis complex and multidrug-resistant isolates in pulmonary and extrapulmonary specimens. J Clin Microbiol. 2016;54(1):59\u201363.","journal-title":"J Clin Microbiol"},{"key":"864_CR26","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.meegid.2016.09.004","volume":"45","author":"AN Unissa","year":"2016","unstructured":"Unissa AN, Subbian S, Hanna LE, Selvakumar N. Overview on mechanisms of isoniazid action and resistance in Mycobacterium tuberculosis. Infect Genet Evol. 2016;45:474\u201392.","journal-title":"Infect Genet Evol"},{"key":"864_CR27","unstructured":"Dheda K, Gumbo T, Maartens G, Dooley KE, McNerney R, Murray M, Furin J, Nardell EA, London L, Lessem E et al. The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis. Lancet Respir Med 2017."},{"issue":"1","key":"864_CR28","doi-asserted-by":"publisher","first-page":"e0163123","DOI":"10.1128\/spectrum.01631-23","volume":"12","author":"M Qadir","year":"2024","unstructured":"Qadir M, Faryal R, Khan MT, Khan SA, Zhang S, Li W, Wei DQ, Tahseen S, McHugh TD. Phenotype versus genotype discordant rifampicin susceptibility testing in tuberculosis: implications for a diagnostic accuracy. Microbiol Spectr. 2024;12(1):e0163123.","journal-title":"Microbiol Spectr"},{"key":"864_CR29","doi-asserted-by":"crossref","unstructured":"Shea J, Halse TA, Kohlerschmidt D, Lapierre P, Modestil HA, Kearns CH, Dworkin FF, Rakeman JL, Escuyer V, Musser KA. Low-level rifampin resistance and rpoB mutations in Mycobacterium tuberculosis: an analysis of whole-genome sequencing and drug susceptibility test data in New York. J Clin Microbiol 2021, 59(4).","DOI":"10.1128\/JCM.01885-20"},{"issue":"1","key":"864_CR30","doi-asserted-by":"publisher","first-page":"e0208721","DOI":"10.1128\/spectrum.02087-21","volume":"10","author":"W Wang","year":"2022","unstructured":"Wang W, Liu R, Yao C, Huo F, Shang Y, Zhang X, Wang Y, Xue Z, Ma L, Pang Y. Reevaluating rifampicin breakpoint concentrations for Mycobacterium tuberculosis isolates with disputed rpoB mutations and discordant susceptibility phenotypes. Microbiol Spectr. 2022;10(1):e0208721.","journal-title":"Microbiol Spectr"},{"key":"864_CR31","doi-asserted-by":"crossref","unstructured":"Koser CU, Georghiou SB, Schon T, Salfinger M. On the consequences of poorly defined breakpoints for rifampin susceptibility testing of Mycobacterium tuberculosis complex. J Clin Microbiol 2021, 59(4).","DOI":"10.1128\/JCM.02328-20"},{"key":"864_CR32","unstructured":"WHO consolidated guidelines on tuberculosis. Module 4: treatment - drug-resistant tuberculosis treatment, 2022 update. WHO Guidelines Approved by the Guidelines Review Committee. Geneva 2022."},{"issue":"1","key":"864_CR33","doi-asserted-by":"publisher","first-page":"e1003008","DOI":"10.1371\/journal.pmed.1003008","volume":"17","author":"AS Dean","year":"2020","unstructured":"Dean AS, Zignol M, Cabibbe AM, Falzon D, Glaziou P, Cirillo DM, Koser CU, Gonzalez-Angulo LY, Tosas-Auget O, Ismail N, et al. Prevalence and genetic profiles of isoniazid resistance in tuberculosis patients: A multicountry analysis of cross-sectional data. PLoS Med. 2020;17(1):e1003008.","journal-title":"PLoS Med"},{"issue":"6","key":"864_CR34","doi-asserted-by":"publisher","first-page":"814","DOI":"10.5588\/ijtld.12.0847","volume":"17","author":"P Kateruttanakul","year":"2013","unstructured":"Kateruttanakul P, Unsematham S. Drug resistance among new smear-positive pulmonary tuberculosis cases in Thailand. Int J Tuberc Lung Dis. 2013;17(6):814\u20137.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"3","key":"864_CR35","doi-asserted-by":"publisher","first-page":"e0346223","DOI":"10.1128\/spectrum.03462-23","volume":"12","author":"A Prommi","year":"2024","unstructured":"Prommi A, Wongjarit K, Petsong S, Somsukpiroh U, Faksri K, Kawkitinarong K, Payungporn S, Rotcheewaphan S. Co-resistance to isoniazid and second-line anti-tuberculosis drugs in isoniazid-resistant tuberculosis at a tertiary care hospital in Thailand. Microbiol Spectr. 2024;12(3):e0346223.","journal-title":"Microbiol Spectr"}],"container-title":["Annals of Clinical Microbiology and Antimicrobials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12941-026-00864-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12941-026-00864-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12941-026-00864-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T02:42:13Z","timestamp":1786416133000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12941-026-00864-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,30]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["864"],"URL":"https:\/\/doi.org\/10.1186\/s12941-026-00864-5","relation":{},"ISSN":["1476-0711"],"issn-type":[{"value":"1476-0711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,30]]},"assertion":[{"value":"19 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study protocol was approved by the Ethics Committee of the Institutional Review Board of the Faculty of Medicine, Chulalongkorn University (COA No. 0761\/2023), in accordance with the ethical principles of the Declaration of Helsinki, and by the Institutional Biosafety Committee of the Faculty of Medicine, Chulalongkorn University (MDCU-IBC No. 045\/2024). Written informed consent was obtained from all participants prior to any procedures undertaken.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"28"}}